RBP Platform Partnerships Sardona's proprietary RBP Topography Map links RNA-binding proteins to therapy-resistant cancers, creating a compelling case for licensing access or co-development with pharma and biotech partners. The platform also includes screening assays, bioinformatics capabilities, and focused small-molecule libraries that external teams can leverage to accelerate discovery. A business development approach is to pursue strategic alliances for platform access and milestone-based discovery collaborations.

Lean Collaboration Model With a small team and early-stage revenue, Sardona is well positioned for sponsor-driven discovery services, exclusive access arrangements, or CRO-style partnerships that minimize internal resourcing while accelerating project timelines. Partners can benefit from a lower-risk, milestone-based model that aligns with early-stage validation and reduces upfront investment.

Cross-Indication Opportunities Although rooted in oncology, the RBP-targeting platform is positioned to identify novel drug leads across non-oncology diseases, such as autoimmune or neurodegenerative conditions. This allows for cross-indication licensing and multi-target discovery programs, expanding the total addressable market for potential collaborations.

IP Positioning Targeting RNA-binding proteins represents a differentiated mechanism with growing interest from the biopharma community. Joint development or license deals around specific RBPs can be structured with clear IP terms to protect both parties and accelerate value creation.

Digital and Market Access Based in San Francisco and supported by modern digital tools and analytics, Sardona is well-placed to engage US-based biotech and pharma partners. The combination of proximity to the Bay Area ecosystem and a data-driven discovery platform can help shorten partner discussions and streamline collaboration onboarding.